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Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with standard
disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA).
Methods: Patients with active RA despite treatment with DMARDs or prior treatment with a tumour necrosis
factor antagonist participated in a multicentre, open-label clinical study of adalimumab 40 mg every other
week for 12 weeks with an optional extension phase. Patients were allowed to continue with pre-existing
traditional DMARDs. Long-term safety results are reported for all patients (4210 patient-years (PYs) of
adalimumab exposure). The observed effectiveness results at week 12 are reported using American College
of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria.
Results: Among the 6610 treated patients, adalimumab was generally well tolerated. Serious infections occurred
in 3.1% of patients (5.5/100 PYs, including active tuberculosis, 0.5/100 PYs). Demyelinating disease (0.06%)
and systemic lupus erythematosus (0.03%) were rare serious adverse events. The standardised incidence ratio of
malignancy was 0.71 (95% CI 0.49 to 1.01). The standardised mortality ratio was 1.07 (95% CI 0.75 to 1.49).
At week 12, 69% of patients achieved an ACR20 response, 83% a moderate, and 33% a good EULAR response.
Adalimumab was effective in combination with a variety of DMARDs. The addition of adalimumab to
antimalarials was comparably effective to the combination of adalimumab and methotrexate.
Conclusions: Considering the limitations of an open-label study, adalimumab alone or in combination with
standard DMARDs appeared to be well tolerated and effective in 6610 difficult-to-treat patients with active
RA treated in clinical practice.
T
umour necrosis factor (TNF) antagonists are effective in
the treatment of rheumatoid arthritis (RA), particularly
when combined with methotrexate (MTX).1–3 However, a
detailed assessment of TNF antagonist therapy in combination
with the wide range of traditional disease-modifying antirheu-
matic drugs (DMARDs) commonly used to treat patients with
RA in clinical practice is lacking.4–13
The ReAct (Research in Active Rheumatoid Arthritis) study
was initiated to assess the safety and effectiveness of
adalimumab, a fully human IgG1 anti-TNF monoclonal anti-
body (1) in combination with a variety of DMARDs and
DMARD combinations and (2) in patients previously treated
with etanercept or infliximab. The open-label design limits the
strength of the conclusions that can be drawn from the data,
but allowed the collection of data from more than 6000 patients
with RA being treated in a variety of clinical practice settings.
Because this was not a randomised, placebo-controlled design
to compare the effect of adalimumab with placebo, the term
‘‘effectiveness’’ is used. Safety data for the entire study period
and an overview of adalimumab effectiveness in combination
with various DMARDs from the initial 12 weeks of the study
are presented here. A detailed analysis for patients who were




Eligible patients were men and women >18 years of age with
active, adult-onset RA in accordance with the 1987 revised criteria
of the American College of Rheumatology (ACR).14 Inclusion
criteria required a disease duration of >3 months, a Disease
Activity Score based on erythrocyte sedimentation rate and an
evaluation of 28 joints (DAS28) of >3.2,15 and treatment failure
with at least one traditional DMARD. Exclusion criteria included:
current pregnancy or breast feeding; any persistent or severe
infection within 30 days of baseline; previous treatment with
other TNF antagonists up to 2 months before enrolment;
treatment with alkylating agents, total lymphoid irradiation,
intravenous immunoglobulin or any investigational biologic
agent; a history of active arthritis other than RA; any uncontrolled
Abbreviations: ACR, American College of Rheumatology; AE, adverse
event; AM, antimalarials; AZA, azathioprine; CsA, ciclosporin; DAS,
Disease Activity Score; DMARD, disease-modifying antirheumatic drug;
EULAR, European League Against Rheumatism; HAQ DI, Health
Assessment Questionnaire Disability Index; LEF, leflunomide; MTX,
methotrexate; PY, patient-year; RA, rheumatoid arthritis; SAE, serious
adverse event; SEER, Surveillance, Epidemiology, and End Results; SIR,
standardised incidence ratio; SSZ, sulfasalazine; TB, tuberculosis; TNF,
tumour necrosis factor
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medical condition; a history or signs of demyelinating disease;
active tuberculosis (TB) or histoplasmosis; malignancy (except for
completely treated squamous or basal cell carcinoma).
All patients underwent Mantoux testing for latent TB. A skin
induration >5 mm was considered a positive result by the
investigator unless national guidelines required a different
threshold. Adequate treatment in accordance with national
guidelines had to be initiated for latent TB before the first
injection of adalimumab unless proper prior treatment for TB
was documented.
All study centres received approval from independent ethics
committees and conducted the study in accordance with
principles of the Declaration of Helsinki. Each patient gave
written informed consent before any study-related procedures
were performed.
Procedures
ReAct was a 12-week, open-label, multicentre study with an
optional extension phase until adalimumab became commer-
cially available. Patients could enter a subsequent postmarket-
ing observational study of adalimumab for up to 5 years. The
dosage regimen was a subcutaneous injection of adalimumab
40 mg (Abbott Laboratories, Abbott Park, Illinois, USA) every
other week. Patients were allowed to continue treatment with
DMARDs (defined as MTX, leflunomide (LEF), sulfasalazine
(SSZ), chloroquine or hydroxychloroquine (antimalarials, AM),
azathioprine (AZA), and parenteral or oral gold) or any
combination of DMARDs, glucocorticoids (prednisone equiva-
lent (10 mg/day), and non-steroidal anti-inflammatory drugs
if the treatment regimens were not modified until week 12.
Ciclosporin (CsA) was not allowed as a concomitant DMARD as
a general precaution against excessive immunosuppression.
Safety, including physical examinations, laboratory measure-
ments and adverse event (AE) reports, and effectiveness were
evaluated at weeks 2, 6, 12, and every 8 weeks thereafter.
Measures of effectiveness were: ACR 20% (ACR20), 50%
(ACR50) and 70% (ACR70) improvement responses;16
European League Against Rheumatism (EULAR) responses;17
changes in DAS28; and changes in ACR component variables,
including the Health Assessment Questionnaire Disability
Index (HAQ DI).18
Statistical analysis
Patients who received at least one adalimumab injection were
included in all analyses. The duration of adalimumab exposure
was defined as the number of days from the first to the last
injection plus 14 days.
Subgroup analyses were performed for patients receiving
adalimumab monotherapy (defined as no concomitant DMARD
irrespective of combination with glucocorticoids or non-
steroidal anti-inflammatory drugs) versus combination therapy
with at least one DMARD. Patients were further stratified by:
the number of concomitant DMARDs (one, two, three or more);
the specific single DMARD (defined as exclusive treatment with
MTX, LEF, SSZ, AM, or a single other DMARD not previously
listed); the DMARD combinations (ie, MTX+LEF, MTX+AM,
MTX+SSZ, and MTX+SSZ+AM). Safety analyses for all patients
and for the major subsets without versus with concomitant
DMARD therapy were performed for the complete treatment
period (up to 70 days (five half-lives) after the last adalimumab
injection), whereas analyses of the detailed DMARD subgroups
were limited to the first 12 weeks of treatment, during which
changes in DMARD therapy were not allowed.
A multiple Cox proportional hazards model was used to
assess possible predictors of serious infection. The following
potential predictors at baseline of serious infection were
specified a priori: age (years); sex; medical history of diabetes
mellitus, cardiac or pulmonary disease; tobacco use (ever);
duration of RA (years); number of previous DMARDs; previous
anti-TNF treatment; rheumatoid factor (+/2); DAS28; HAQ DI
score; C-reactive protein concentration; leucopenia (,3.5/nl);
glucocorticoid use; and LEF use.19–21
The standardised mortality ratio was calculated using the
most recent World Health Organization Statistical Information
System (WHOSIS) data for the 12 countries where ReAct was
conducted.22 The standardised incidence ratio (SIR) of the
observed malignancies in ReAct was determined by comparison
with the expected number of cancers in a cohort matched for
age and sex using the National Cancer Institute Surveillance,
Epidemiology, and End Results (SEER) database in place of the
multinational European cancer database.23
Effectiveness data are presented as observed values at week
12. The mean changes in DAS28, HAQ DI scores, and tender


























All patients (n = 6610) 54 (13) 81 73 11 (9) 3.0 (1.8) 71 6.0 (1.1) 1.64 (0.68) 14 (7) 10 (6) 26 (31)
Number of concomitant DMARDs
No DMARDs (n = 1731) 55 (13) 82 72 12 (9) 3.1 (2.1) 70 6.2 (1.1) 1.73 (0.68) 14 (7) 11 (6) 29 (35)
>1 DMARD (n = 4879) 53 (13) 80 73 10 (8) 2.9 (1.7) 72 6.0 (1.1) 1.60 (0.68) 13 (7) 10 (6) 25 (29)
1 DMARD (n = 4004) 53 (13) 81 73 10 (8) 2.8 (1.7) 71 6.0 (1.1) 1.61 (0.68) 13 (7) 10 (6) 24 (28)
2 DMARDs (n = 769) 53 (13) 75 74 9 (7) 3.3 (1.5) 75 6.0 (1.1) 1.55 (0.69) 13 (7) 11 (6) 27 (32)
>3 DMARDs (n = 106) 52 (12) 76 76 10 (9) 3.8 (1.2) 67 5.9 (1.1) 1.68 (0.65) 13 (7) 12 (7) 32 (43)
One exclusive concomitant DMARD
MTX only (n = 2794) 53 (13) 82 73 10 (8) 2.7 (1.7) 70 6.0 (1.1) 1.61 (0.68) 13 (7) 10 (6) 23 (27)
LEF only (n = 842) 54 (12) 82 75 11 (9) 3.3 (1.7) 73 6.0 (1.1) 1.58 (0.68) 13 (7) 11 (6) 24 (28)
SSZ only (n = 133) 56 (13) 81 69 11 (8) 3.1 (1.8) 63 6.1 (1.1) 1.70 (0.71) 14 (8) 11 (6) 30 (32)
AM only (n = 148) 56 (12) 83 74 8 (7) 2.8 (1.8) 78 6.2 (1.0) 1.62 (0.69) 15 (7) 10 (6) 28 (30)
1 other DMARD* (n = 84) 55 (13) 79 68 13 (9) 4.1 (2.1) 81 6.3 (1.0) 1.87 (0.69) 14 (7) 11 (5) 30 (33)
DMARD combinations
MTX+LEF (n = 180) 53 (13) 79 72 10 (8) 3.5 (1.6) 81 6.1 (1.0) 1.55 (0.64) 13 (7) 11 (6) 27 (35)
MTX+AM (n = 269) 52 (13) 75 76 8 (7) 2.9 (1.4) 74 6.0 (1.1) 1.52 (0.7) 14 (7) 10 (6) 23 (27)
MTX+SSZ (n = 182) 52 (13) 70 72 9 (8) 3.0 (1.3) 69 5.9 (1.1) 1.57 (0.7) 13 (7) 11 (6) 28 (33)
MTX+SSZ+AM (n = 76) 53 (12) 78 71 9 (8) 3.7 (1.2) 66 5.9 (1.2) 1.69 (0.66) 13 (8) 12 (7) 37 (46)
AM, antimalarials; AZA, azathioprine; CRP, C-reactive protein; CsA, ciclosporin; DAS28, Disease Activity Score 28; DMARDs, disease-modifying antirheumatic drugs;
HAQ DI, Health Assessment Questionnaire Disability Index; LEF, leflunomide; MTX, methotrexate; RF+, rheumatoid factor positive; SJC, swollen joint count; SSZ,
sulfasalazine; TJC, tender joint count.
Data are mean (SD) unless otherwise noted.
*Of these 84 patients, 51% were receiving AZA, 27% were receiving parenteral gold, 17% were receiving CsA, and 5% were receiving penicillamine.
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and swollen joint counts from baseline to week 12 were
analysed by paired t test. Adjustment for baseline differences
between treatment subgroups was performed with the combi-
nation of adalimumab and MTX as the reference group. Logistic
regression analyses were used for the following dichotomous
end points: ACR20, 50, 70 responses, moderate and good
EULAR responses, and DAS28. Possible confounders were
identified as age (years), sex, duration of RA (years), baseline
DAS28, baseline HAQ DI score, number of previous DMARDs,
and comorbidities (none or one versus two or more). The
number of baseline comorbidities was identified during the
medical history review of gastrointestinal, cardiovascular,
metabolic, genitourinary, neurological and psychiatric, pul-
monary, and whole body disorders.
RESULTS
Patient disposition and withdrawals
Of 6610 patients enrolled at 448 study centres in 12 countries,
3721 (56.3%) were treated in hospital-based clinics, 2428
(36.7%) in university-based hospitals, and 461 (7.0%) in private
practice. At week 12, 93% (6140) of 6610 enrolled patients
continued in the study; 4.3% withdrew because of AEs and
1.4% because of lack of adalimumab effectiveness. During the
complete adalimumab treatment period, 10.3% (682) of 6610
patients withdrew because of AEs and 6.8% (450) because of
lack of adalimumab effectiveness. The number of patients over
time was 6538 (week 2), 6218 (week 6), 6140 (week 12), 5230
(week 20), 4119 (week 28), 3021 (week 36), 1251 (week 52),
and 702 (week 60), with a mean/median adalimumab exposure
of 233/211 days (maximum 669 days).
Baseline patient characteristics
Table 1 summarises baseline patient characteristics. Although
CsA was an excluded DMARD, 25 patients received CsA
concomitantly, and data for these patients were included in
all analyses. Before study entry, MTX, LEF, AM, SSZ, parenteral
gold, CsA and infliximab had been prescribed for 89%, 42%,
42%, 39%, 28%, 16% and 11%, respectively, of all enrolled












All serious adverse events 28.4 40.0 24.6
Blood and lymphatic system disorders* 0.5 1.2 0.3
Anaemias (non-haemolytic and marrow depression) 0.4 0.9 0.3
Cardiac disorders* 1.4 1.9 1.3
Heart failures 0.4 0.8 0.3
Gastrointestinal disorders* 1.4 1.8 1.2
General disorders and administration site conditions* 1.5 1.9 1.4
Hepatobiliary disorders* 0.4 0.8 0.3
Immune system disorders* 0.2 0.4 0.2
Allergic conditions 0.2 0.4 0.2
Infections and infestations* 5.5 6.6 5.1
Lower respiratory tract and lung infections` 1.0 1.2 1.0
Abdominal and gastrointestinal infections` 0.4 1.0 0.2
Sepsis, bacteraemia and viraemia` 0.4 0.5 0.4
Bone and joint` 0.1 0.2 0.1
Injury, poisoning and procedural complications* 2.1 3.3 1.7
Musculoskeletal and connective tissue disorders* 6.9 11.0 5.5
Joint disorders 5.3 8.5 4.3
Neoplasm benign, malignant, and unspecified (including
cysts and polyps)*
1.1 1.3 1.0
Malignancy1 1.1 1.2 1.0
Nervous system disorders* 1.3 1.7 1.2
Renal and urinary disorders* 0.5 0.6 0.5
Reproductive system and breast disorders* 0.4 0.8 0.3
Respiratory, thoracic, and mediastinal disorders* 1.3 1.3 1.3
Parenchymal lung disorders (not elsewhere classified)` 0.2 0.3 0.2
Skin and subcutaneous tissue disorders* 0.5 0.8 0.4
Surgical and medical procedures* 1.1 0.9 1.1
Vascular disorders* 0.8 1.0 0.8
DMARDs, disease-modifying antirheumatic drugs; MedDRA, Medical Dictionary for Regulatory Activities.
*MedDRA System Organ Class term.
MedDRA High Level Group term.
`MedDRA High Level term.
1Includes all neoplasms not explicitly reported as benign.




dichotomous) Hazard ratio 95% CI p Value
Pulmonary disease Yes versus no 1.53 1.14 to 2.06 ,0.0048
Male sex Yes versus no 1.48 1.07 to 2.06 ,0.0187
HAQ DI score (points) Continuous 1.42 1.14 to 1.77 ,0.0017
Cardiac disease Yes versus no 1.43 1.06 to 1.93 ,0.0179
Age (years) Continuous 1.02 1.01 to 1.03 ,0.0073
HAQ DI, Health Assessment Questionnaire Disability Index.
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patients (previous drugs for ,10% of patients are not shown).
Of the 6610 patients, 2252 had no or one comorbid condition,
and 4358 had two or more comorbid conditions.
Safety
Complete treatment period for all patients
This study represents 4210 patient-years (PYs) of adalimumab
exposure. For the 72.4% of patients (4783/6610) who reported
an AE, the three most common were RA-related events (9.7%
(641/6610)), headache (4.8% (317/6610)) and nasopharyngitis
(4.4% (293/6610)), and 9% were considered severe. Serious AEs
(SAEs) occurred in 13% (882/6610) of patients (equivalent to
28.4 SAEs/100 PYs) (table 2). The three most commonly
reported SAEs were RA-related events (2.0% (135/6610)),
pyrexia (0.4% (25/6610)) and osteoarthritis (0.3% (20/66100).
Serious infections were reported for 202 of 6610 patients.
Independent predictors for serious infection were pulmonary
disease, male sex, higher HAQ DI score, cardiac disease, and
increased age (table 3). Serious opportunistic infections (not
including TB) occurred in ,0.1% (6/6610) of patients and were
caused by Candida (n = 1), cytomegalovirus (n = 3), Listeria
monocytogenes (n = 1) and Toxoplasma gondii (n = 1).
Of the 6610 patients, 12.6% (832) had a positive Mantoux
test result, and 3% (196) had a chest radiograph indicative of
previous TB infection. Preventive treatment for latent TB
infection was initiated in 835 patients (12.6%). Overall, 21
patients (mean age 60 years) were reported to have developed
active TB (0.5/100 PYs); the diagnosis was confirmed by culture
in 12 (57%) patients, was based on tissue staining of acid-fast
bacilli in four patients, and was not confirmed in five patients.
Of these 21 patients, eight had been screened with a Mantoux
test that resulted in skin induration >5 mm in diameter.
However, only four of these eight patients had standard
treatment for latent TB initiated (isoniazid 300 mg daily);
treatment with isoniazid for one patient was stopped after
6 months, consistent with the national guideline. Isoniazid
prophylaxis was not initiated in the other four patients because
the threshold for latent TB treatment based on Mantoux testing
was defined as skin induration >10 mm in diameter by
national guidelines, the patient had been immunised with the
bacille Calmette-Gue´rin vaccine, or the patient had been
recently treated with isoniazid for 11 months. The median
interval from the first adalimumab injection to diagnosis of TB
was 6 months (range 1–14). Eleven patients had extrapulmon-
ary TB. The death of a woman aged 86 years who refused
tuberculostatic treatment because of major gastrointestinal
intolerance was attributed to TB.
Demyelinating disorders (all SAEs) occurred in 0.06% (4/
6610) of patients as follows: multiple sclerosis (n = 1) and
central demyelination (n = 1) (each confirmed by cerebral
MRI), and Guillain-Barre´ syndrome (peripheral demyelination)
(n = 2). Systemic lupus erythematosus based on an investiga-
tor’s report was reported as an SAE for two of 6610 patients
(0.03%).
Of 18 patients with congestive heart failure reported as an
SAE (0.3%), 13 had pre-existing cardiovascular disorders
(excluding peripheral vascular diseases).
The haematological AE rate was similar in patients receiving
adalimumab with and without DMARDs (1.3% and 1.4%,
respectively), whereas AEs of anaemia were more often
considered serious for patients receiving adalimumab alone.
Most haematological SAEs reported were unspecified or
microcytic anaemia. Bone marrow toxicity and pancytopenia
were reported in one patient each, both receiving concomitant
DMARDs.
Forty three of 6610 patients had neoplasms that were
counted as malignancies (the definition of neoplasms included
those with no explicit benign character). For the SIR calcula-
tion, basal cell carcinoma and carcinoma in situ were excluded
in accordance with the SEER algorithm. The total number of
malignancies (32) was lower than expected (44.8), resulting in
an SIR of 0.71 (95% CI 0.49 to 1.01) for malignancies in
adalimumab-treated patients. The SIR for lymphomas was 1.09
(95% CI 0.12 to 3.95) based on the number of lymphomas
observed (2) compared with the number expected (1.83).
The standardised mortality ratio was 1.07 (95% CI 0.75 to
1.49), with 35 deaths observed compared with 32.6 deaths
expected in the general population.
Table 4 Observed adalimumab effectiveness at week 12
Patient group





















All patients (n = 6610) 22.1 (1.4) 235.4 20.54 (0.61) 234.0 28.0 273.3 26.0 272.7 25.5 244.4
Number of concomitant
DMARDs
No DMARDs (n = 1731) 21.9 (1.4) 229.7 20.47 (0.63) 227.2 27.0 266.7 26.0 266.7 24.5 231.4
>1 DMARD (n = 4879) 22.2 (1.3) 237.3 20.56 (0.60) 236.4 28.0 275.0 26.0 275.0 25.7 247.8
1 DMARD (n = 4004) 22.2 (1.3) 237.2 20.56 (0.6) 236.3 28.0 275.0 26.0 275.0 25.5 247.3
2 DMARDs (n = 769) 22.3 (1.3) 238.0 20.56 (0.6) 236.8 28.0 275.0 26.0 275.0 27.0 250.5
>3 DMARDs (n = 106) 22.3 (1.3) 239.6 20.56 (0.57) 235.2 29.0 280.0 27.0 275.0 25.7 250.7
1 exclusive concomitant
DMARD
MTX (n = 2794) 22.3 (1.3) 238.3 20.58 (0.6) 238.4 28.0 275.0 26.0 275.0 25.4 247.5
LEF (n = 842) 22.0 (1.3) 233.7 20.49 (0.59) 229.5 28.0 275.0 26.0 269.2 25.4 244.6
AM (n = 148) 22.4 (1.4) 237.9 20.72 (0.63) 246.0 29.0 275.0 27.0 279.2 28.1 252.3
SSZ (n = 133) 22.1 (1.3) 234.2 20.52 (0.62) 229.6 27.0 266.7 26.0 266.7 28.9 254.2
1 other DMARD (n = 84) 22.2 (1.2) 235.1 20.55 (0.55) –27.1 28.0 272.1 27.0 268.4 29.7 249.2
DMARD combinations
MTX+LEF (n = 180) 22.2 (1.3) 236.4 20.54 (0.58) 236.3 29.0 276.9 27.0 278.9 26.0 246.2
MTX+AM (n = 269) 22.4 (1.3) 239.2 20.63 (0.66) 241.3 28.0 276.3 26.0 276.4 24.7 251.4
MTX+SSZ (n = 182) 22.4 (1.3) 239.8 20.55 (0.52) 238.8 28.0 276.4 26.0 275.0 210.1 256.7
MTX+SSZ+AM (n = 76) 22.4 (1.3) 240.7 20.58 (0.59) 237.6 27.0 280.0 27.0 275.8 27.8 255.2
AM, antimalarials; AZA, azathioprine; CRP, C-reactive protein; CsA, ciclosporin; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug;
HAQ DI, Health Assessment Questionnaire Disability Index; LEF, leflunomide; MTX, methotrexate; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count.
Absolute change is given as mean (SD) or median.
*All changes in DAS28 and HAQ DI scores were significantly improved compared with baseline values (p(0.001).
Of these 84 patients, 51% were receiving AZA, 27% were receiving parenteral gold, 17% were receiving CsA, and 5% were receiving penicillamine.
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Safety up to week 12
Monotherapy or various numbers of concomitant DMARDs
Of the 4879 patients who received adalimumab and at least one
concomitant DMARD, 260 (5.3%) reported an SAE. Of the 1731
patients receiving no concomitant DMARDs, 126 (7.3%) reported
an SAE. RA-related events were the most commonly reported
SAE in patients receiving concomitant DMARD therapy (2.5/
100 PYs) or adalimumab monotherapy (6/100 PYs). SAEs were
reported less often for patients receiving adalimumab in
combination with DMARDs (only one DMARD (5.5%), two
DMARDs (4.4%), or at least three DMARDs (3.8%)) compared
with patients receiving no concomitant DMARDs (7.3%).
Single concomitant DMARDs
The SAE rates for patients receiving adalimumab and only one
concomitant DMARD were 4.1% for AM, 4.6% for MTX, 8.2%
for LEF and 9.0% for SSZ. The serious infection rate was low in
patients treated with a combination of adalimumab and MTX
(1.1%), LEF (1.9%), AM (2.0%) or SSZ (2.3%), and was similar
to the rate in patients receiving adalimumab alone (1.7%).
Figure 1 American College of
Rheumatology 20% (ACR20), 50% (ACR50),
and 70% (ACR70) improvement and
European League Against Rheumatism
(EULAR) responses to adalimumab treatment
for all patients and by concomitant disease-
modifying antirheumatic drug (DMARD)
subgroup at week 12. The values above the
bars are the percentages of patients
achieving the response criterion. All values
are observed. (A) Responses by number of
concomitant DMARDs; (B) responses by
exclusive concomitant DMARD; (C)
responses by combinations of concomitant
DMARDs. AM, antimalarials; LEF,
leflunomide; MTX, methotrexate; SSZ,
sulfasalazine.
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Cutaneous and subcutaneous AEs were reported in 17.3% of
patients treated with adalimumab and LEF; of these, 0.8% were
SAEs. No SAEs of the skin were documented for patients receiving
concomitant AM or SSZ; SAEs of the skin were reported for 0.1%
of patients treated with adalimumab and MTX.
Combinations of MTX and other concomitant DMARDs
The SAE rate in patients receiving adalimumab and MTX plus
LEF, SSZ or AM was lower than in the groups receiving
adalimumab and only LEF, SSZ or AM respectively. The
percentages of patients with serious infection were 0.0% for
MTX+SSZ, 1.1% for MTX+AM, 2.2% for MTX+LEF and 2.6% for
MTX+SSZ+AM. Of 76 patients receiving adalimumab in
addition to MTX+SSZ+AM, four (5.3%) experienced an SAE.
AZA, gold, CsA
Adalimumab was added to AZA alone or in combination with
other DMARDs in 63 patients; two (3.2%) experienced an SAE.
Two of 53 patients treated with adalimumab and parenteral
gold (with or without other DMARDs) experienced an SAE. No
infectious or cutaneous SAEs occurred during combination
therapy with parenteral gold and adalimumab. Of the 25
patients who received CsA (alone or in combination with other
DMARDs) in addition to adalimumab, two (8%) had an SAE.
No change in the safety profile occurred when adalimumab was
combined with AZA, parenteral gold, or CsA.
Effectiveness
The mean absolute and percentage changes in commonly used
disease activity measures showed significant (p(0.001) and
clinically relevant improvements from baseline to week 12 for all
patients and all concomitant DMARD subgroups (table 4). Overall
ACR and EULAR responses are shown in fig 1. At week 12, 25% of
all patients had a HAQ DI ,0.5, and 20% had a DAS28 ,2.6,
which corresponds to fulfilment of the preliminary American
Rheumatology Association criteria for clinical remission in RA.24
Concomitant DMARD subgroups
In the unadjusted univariate analyses, more patients receiving
adalimumab and concomitant DMARDs (regardless of type or
number of DMARDs) achieved ACR and EULAR responses and
experienced more improvement in most measures of effectiveness
than patients receiving adalimumab alone (fig 1 and table 4).
More patients receiving adalimumab and either MTX or AM
achieved ACR and EULAR responses and experienced greater
reductions in disease activity and disability than patients receiving
adalimumab and either SSZ or LEF (fig 1B and table 4).
This pattern of effectiveness among the different DMARDs
was sustained after adjustment for baseline differences among
the patient subgroups. Compared with the reference combina-
tion of adalimumab and MTX, the likelihood of achieving key
effectiveness parameters was most similar (ie, ORs closest to
1.0) when adalimumab was added to AM or to the combination
of MTX plus another DMARD (table 5).
DISCUSSION
This study is the largest prospective clinical evaluation of a TNF
antagonist for the treatment of RA. The safety profile of
adalimumab observed in this study was consistent with that
previously reported for adalimumab, etanercept and inflixi-
mab.1 3 25–27 The range of DMARDs used concomitantly with
adalimumab in ReAct reflected standard treatment for patients
with long-standing severe RA.28–30 No clinically important
differences in the safety profile of adalimumab according to
the number or type of concomitant DMARDs were evident.
Notably, the rate of AEs did not increase as the number and























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adalimumab for rheumatoid arthritis 737
www.annrheumdis.com
that is consistent with use of multiple DMARDs in other
studies.31 32 The combinations of adalimumab and LEF or SSZ
were associated with higher rates of SAEs compared with
patients receiving adalimumab and MTX or AM.
Rheumatoid arthritis and age are both known risk factors for
infection.19 33 The serious infection rate of 5.5/100 PYs is similar
to reports of patients with RA receiving either infliximab or
etanercept in the German and British biologics registries20 34;
these rates were somewhat higher than those seen in patients
treated with conventional DMARDs in these registries. The
identified predictors for a serious infection in this study were
increased age, male sex, comorbid pulmonary and cardiovas-
cular conditions, and a higher baseline HAQ DI score.
All patients were carefully screened for latent TB before
enrolment. In total, 835 patients (12.6%) received treatment for
latent TB in accordance with national guidelines. Overall,
published literature indicates that the rate of active TB has
decreased since the initiation of routine screening for latent TB
in patients receiving TNF antagonists.27 35 In the present study,
the rate of TB (0.5/100 PYs) remains higher than expected in
the general population. However, the underlying risk of TB in
patients with RA seems to exceed that of the background
population.35 36
The SIRs of 0.71 for malignancies and 1.09 for lymphoma in
this study are consistent with rates observed in patients with
RA (SIR of 0.9821.1 for malignancies overall and SIR of
1.0211.5 for lymphoma).13 37–39 A meta-analysis of pooled AE
data from randomised, controlled trials suggested an OR of 3.3
(95% CI 1.2 to 9.1) for malignancies.40 Calculation of SIRs based
on population-based incidence data and determination of ORs
based on meta-analytical methodology both have limitations.
Analysis of a clinical trial safety database of 10 050 adalimu-
mab-treated patients with RA reported an SIR of 1.06 for
malignancies overall and an SIR of 3.19 for lymphoma.27
Notably, there is a strong association between inflammatory
activity and lymphoma in patients with RA.41 The standardised
mortality ratio of 1.07 (95% CI 0.75 to 1.49) was slightly lower
than the expected range for patients with RA.42
Adalimumab provided substantial improvement in multiple
measures of effectiveness in patients with long-standing active
RA despite extensive standard treatment. Randomised, con-
trolled trials have shown that significantly more patients
experience a reduction of disease activity when treated with
MTX and a TNF antagonist versus a TNF antagonist alone.1–3
After adjustment for differences in baseline characteristics in
this study, patients receiving adalimumab and an AM had a
similar therapeutic response to the patients receiving adalimu-
mab and MTX. Concomitant treatment with adalimumab and
LEF was found to be slightly less effective than concomitant
treatment with adalimumab and MTX, AM or SSZ but more
effective than adalimumab alone after adjustment for differ-
ences in baseline characteristics between subgroups.
Although a placebo-controlled trial is necessary to prove the
efficacy of a drug, an open-label study conducted in a large
cohort of patients in multiple countries and a variety of clinical
practice sites should provide reassurance about the safety and
effectiveness of adalimumab in typical practice. The ACR20
response rates in ReAct were within the range reported in
randomised, double-blind studies of adalimumab.1 25 43 44 The
duration of RA and baseline disease activity of participants
reflect the RA population typically treated with TNF antagonists
and are consistent with most national guidelines for this
treatment. By comparison with national biologic registers,
which observe treatment outcomes associated with a variety of
biologics for several years, this was an industry-sponsored
clinical study conducted in 12 countries with careful site
monitoring for a limited treatment period.
CONCLUSIONS
Adalimumab alone or in combination with standard DMARDs
appeared to be well tolerated and effective in 6610 patients with
active RA despite numerous previous antirheumatic treatments
and various comorbid medical disorders. There were no
unexpected safety concerns with the addition of adalimumab
to existing DMARD regimens.
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